Theratechnologies pulls cross-border offering

Theratechnologies’ (TSX:TH) board of directors has decided to withdraw its public offering in Canada and the U.S. because of the expected offering price, which was not acceptable to the company. Shares of Theratechnologies have been on a downward spiral since the proposed offering was announced on Feb. 22, sliding from $5.01 to Tuesday’s close of [...]

Analysts hike price target on Theratechnologies

Versant Partners and Canaccord Genuity raised their price targets on Theratechnologies (TSX:TH) after the company signed a partnership with Sanofi-Aventis to distribute its Egrifta HIV treatment in Latin America, Africa and the Middle East, and confirmed that the U.S. selling price of the drug would be $23,900 (U.S.) a year, higher than previously assumed. Cannacord [...]

Canaccord ups Theratechnologies on FDA approval

Canaccord Genuity has raised its price target on Theratechnologies (TSX:TH) to $7.85 from $7 after the FDA approved the company’s lead drug Egrifta for the treatment of HIV lipodystrophy, a metabolic disorder associated with HIV.  The stock closed at $5 on Wednesday. Analyst Neil Maruoka writes that he expects Egrifta to be launched in the [...]

Theratechnologies picks Huss as president, CEO

Theratechnologies (TSX:TH) has named John-Michel Huss as president and CEO, succeeding Yves Rosconi, who previously informed the board of his decision to retire by the end of the year. Mr. Huss will assume the two posts in coming months. He was most recently chief of staff, office of the CEO, of Sanofi-Aventis in Paris and has [...]

FDA delays action date for Theratechnologies

Theratechnologies (TSX:TH) expects to have an official response from the FDA in the fourth quarter this year about its new drug application for its tesamorelin, a treatment for excess abdominal fat in HIV-infected patients with lipodystrophy. The FDA had originally targeted July 27 to complete its review. “The FDA has indicated that the review is [...]

BIOTECanada’s Peter Benders on the state of the sector

What top three big-picture issues face biotech firms in Canada in the foreseeable future?  Top of the list is, of course, financing.  Even after an economically difficult year that saw global markets shy away from “risky” investments like biotech, within the industry, much scepticism remains about capital coming back.  On the one hand, we see [...]

Theratechnologies CEO retires; Amorfix’s steps down

Yves Rosconi, CEO and President of Theratechnologies (TSX:TH), has informed the board of his decision to retire on Dec. 31, 2010, saying he deferred his decision until the company’s lead tesamorelin product was in the final stages of the FDA approval process. A strategic committee of the board will immediately begin the formal search for [...]

Theratechnologies riding wave of optimism

Shares of Theratechnologies (TSX:TH) jumped Friday after an FDA advisory committee on Thursday evening unanimously recommended the FDA green light the company’s tesamorelin drug to treat excess abdominal fat in HIV-infected patients with lipodystrophy, based on a favourable benefit-risk profile. The stock, which slumped earlier in the week after the committee’s briefing papers suggested Theratechnologies’ [...]

FDA committee clears Theratechnologies’ tesamorelin

An FDA advisory committee recommended by a 16-to-0 unanimous vote that Theratechnologies’ (TSX:TH) tesamorelin drug should be granted marketing approval by the FDA for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy, based on a favourable benefit-risk profile. “This recommendation reinforces our belief that the tesamorelin benefit-risk profile seen in clinical trials [...]

RBC ups Theratechnologies to buy

Citing a recent sell-off and upcoming milestones, RBC Capital Markets upgraded Theratechnologies (TSX:TH) to “outperform” from “sector perform,” but kept its price target unchanged at $6.50.  The shares finished at $5.09 on Wednesday after touching a 52-week high of $5.61 earlier this month. “Theratechnologiesis in the enviable position of having a number of important upcoming [...]

Next Page »